STUDY QUESTION: Can supplementation of medium with prolactin (PRL), epidermal growth factor (EGF) and 4-hydroxyestradiol (4-OH-E 2 ) prior to embryo transfer improve implantation potential in mouse blastocysts derived from IVF?
Introduction
The implantation of a blastocyst into the maternal uterus is a crucial step in mammalian reproduction. During the preimplantation period, development of the mammalian embryo involves a dynamic series of events, including fertilization, cell division, establishment of cell polarity, compaction to form a morula and lineage differentiation to form the blastocyst (Wang and Dey, 2006; Piliszek et al., 2016) . This process can be reproduced in vitro and can be monitored using a timelapse imaging system; however, for successful implantation, the blastocyst must attain implantation competency in the receptive uterus Wang and Dey, 2006) . In the uterus, highly co-ordinated cellular and molecular events, directed by ovarian estrogen (E 2 ) and progesterone (P 4 ), produce a receptive environment to support implantation Wang and Dey, 2006; Cha et al., 2012; Matsumoto et al., 2015) , and the blastocyst, with its own molecular program for cell growth and differentiation, functions as an active unit in this process.
Uterine growth factors modulate blastocyst development to achieve temporal synchronization of blastocyst competency with uterine receptivity to implantation, which occurs within a limited time window. Many factors that accelerate blastocyst development have been identified, and their impact on the intracellular signals regulating trophoblast differentiation has been described (Armant, 2005; Yoshinaga, 2008 Yoshinaga, , 2010 Yoshinaga, , 2014 Fritz et al., 2014) . Although there have been several improvements in human IVF techniques over the past 2 decades, live births from ART remain low: on average, about 20% per cycle (Calhaz-Jorge et al., 2016) . Poor quality of IVF-derived embryos is one of the major causes of implantation failure (Urman et al., 2005; Cha et al., 2012) . Therefore, improvement of the implantation efficiency of cultured blastocysts should be a focal point for enhancing the efficacy of IVF, and both the in vitro development of embryos to blastocysts and the implantation competency of the blastocysts should be investigated.
Delayed implantation in mice provides a powerful model for studying blastocyst implantation competency at the molecular level by allowing for comparisons of global gene expression in the blastocysts during dormancy and activation (Hamatani et al., 2004) . Ovariectomy on the morning of Day 4 (Day 1 = vaginal plug) prior to preimplantation E 2 secretion results in blastocyst dormancy and delayed implantation. The conditions for delayed implantation can be maintained by continuous P 4 treatment, but are terminated upon E 2 injection, leading to blastocyst activation and subsequent implantation in the uterus around 24 h after E 2 injection. Using this model, we recently demonstrated that proteasome-mediated protein degradation in activated (implantation-induced) blastocysts is involved in the completion of implantation (Saito et al., 2014; Matsumoto et al., 2016) . Specifically, we observed that selective protein turnover, such as that of estrogen receptor α (ESR1), occurs in implantation-competent blastocysts, while expression of other proteins, including breast cancer 1 (BRCA1), is maintained at the same stage (Saito et al., 2014; Matsumoto et al., 2016) . These findings suggest that the expression patterns of these proteins comprise potential markers of the implantation competency of cultured blastocysts prior to embryo transfer.
Previous studies detected higher BRCA1 expression levels in the trophectoderm (TE) of implantation-induced blastocysts by immunohistochemistry in mice (Hamatani et al., 2004; Saito et al., 2014) . Brca1 is a tumor suppressor gene, and its mutations confer an increased risk for the development of several E 2 -responsive tumors (Struewing et al., 1997; Thompson and Easton, 2002) . Notably, BRCA1 protein expression was upregulated in response to prolactin (PRL) stimulation in the human breast cancer cell lines MCF-7 and T-47D (Favy et al., 1999) . Likewise, stimulation with epidermal growth factor (EGF) resulted in increased BRCA1 expression in MCF-7 cells (Marks et al., 1997) . Therefore, we hypothesized that PRL and EGF may induce BRCA1 expression in blastocysts, thereby enhancing their implantation competence. Although E 2 is essential for blastocyst activation and implantation in the progesterone-primed mouse uterus, embryo transfer experiments in delayed implant recipient mice provided evidence that the catechol estrogen 4-hydroxyestradiol (4-OH-E 2 ), a catechol metabolite produced from primary E 2 in the uterus, participates in the activation of dormant blastocysts (Paria et al., 1998) . Specifically, 4-OH-E 2 is important for blastocyst implantation competency, while E 2 is necessary for preparation of the uterus. Therefore, 4-OH-E 2 might also induce BRCA1 expression in blastocysts derived from IVF and improve their implantation potential.
In the present study, we investigated whether PRL, EGF and 4-OH-E 2 regulate the BRCA1 protein in IVF-derived mouse blastocysts. In addition to BRCA1, we examined the levels of other proteins in IVFderived blastocysts. EGF receptor (EGFR, also known as ERBB1) and ERBB4 (erb-b2 receptor tyrosine kinase 4) are upregulated in the TE of activated blastocysts, while upregulated tubulointerstitial nephritis antigen-like 1 (TINAGL1) localizes to the blastocyst basement membrane (Raab et al., 1996; Paria et al., 1999; Igarashi et al., 2009; Saito et al., 2014) . Therefore, we examined the distribution of EGFR, ERBB4 and TINAGL1 in BRCA1-expressing blastocysts. Furthermore, we assessed the implantation rate of blastocysts treated in vitro with the combination of PRL, EGF and 4-OH-E 2 .
Materials and Methods

Animal model and ethical approval
Adult ICR mice were purchased from Japan SLC (Shizuoka, Japan) and bred in our animal care facility. All animal experimental procedures used in this study were performed in accordance with the instructions of the Figure 1 Upregulation of BRCA1 expression in the trophectoderm of mouse blastocysts treated with PRL, EGF, or 4-OH-E 2 . Blastocysts formed at 90-96 h after IVF were treated with (A) prolactin (PRL), (B) epidermal growth factor (EGF) or (C) 4-hydroxyestradiol (4-OH-E 2 ) for 24 h. Breast cancer 1 (BRCA1) of Single and Composite represent, respectively, one layer and composite confocal images generated from multiple zplanes acquired at 3.0-μm intervals across the blastocyst; scale bar, 50 μm. (D) Cell numbers in the blastocysts treated with PRL, EGF or 4-OH-E 2 . Each treatment did not stimulate cell proliferation (P > 0.05). The data are mean ± SEM. Cell numbers in the blastocysts were compared by oneway factorial ANOVA followed by Fisher's protected least significant difference test. Numbers above each bar indicate examined numbers of blastocysts. 
IVF and embryo culture
IVF and culture of embryos were performed as described previously (Matsumoto et al., 2001 (Matsumoto et al., , 2011 (Matsumoto et al., , 2012 Saito et al., 2014; Takahashi et al., 2016) . Female mice were subjected to superovulation by i.p. injection of 5 IU equine chorionic gonadotropin (eCG) followed by 5 IU hCG 48 h later. Ovulated oocytes were then collected in human tubal fluid (HTF) medium without phenol red (HTF-P) at 14 h after hCG injection. Spermatozoa were pre-incubated for 2-3 h in HTF-P to allow for capacitation; the final concentration was 700 spermatozoa/μL. Four hours after insemination, oocytes were transferred to 100 μL of potassium simplex optimized medium (KSOM) without phenol red (KSOM-P), overlaid with paraffin liquid (Nacalai Tesque, Kyoto, Japan), and cultured in a humidified atmosphere with 5% CO 2 at 37°C for 90-96 h. Blastocysts were then treated with PRL (10 or 20 mIU/mL; Sigma Aldrich Co., St. Louis, MO, USA), EGF (5 or 10 ng/mL; Sigma Aldrich Co.), or 4-OH-E 2 (1 or 10 nM; Sigma Aldrich Co.) in four-well culture plates (Thermo Fisher Scientific, Inc.; Waltham, MA, USA) containing 500 μL of KSOM-P for 24 h, as described previously (Paria and Dey, 1990; Paria et al., 1998; Favy et al., 1999) . The PRL stock solution (40 IU/mL) was prepared in 4 mM HCl containing 1 mg/mL bovine serum albumin. The 4-OH-E 2 stock solution (5 mM) was prepared in ethanol containing 10 mM L-ascorbic acid. Ethanol and L-ascorbic acid were added to the control cultures at a final concentration of 0.1% and 100 nM, respectively.
Immunohistochemical analysis
Immunohistochemistry was performed as described previously Igarashi et al., 2009; Saito et al., 2014) . Embryos were fixed in 3.7% formaldehyde in Ca 2+ -and Mg
2+
-free Dulbecco's phosphate buffered saline (D-PBS) at room temperature for 30 min, permeabilized in 0.25% Tween-20 in D-PBS for 5 min, and incubated overnight at 4°C with primary antibodies specific for BRCA1, EGFR, ERBB4, ESR1 (all from Santa Cruz Biotechnology, Santa Cruz, CA, USA), or TINAGL1 (a generous gift from Dr K. Mukai, Keio University, Tokyo, Japan). After several washes with D-PBS, the embryos were incubated with FITC-(MP Biomedicals, Santa Ana, CA, USA) or Alexa Fluor 647-labeled secondary antibodies (Life Technologies, Carlsbad, CA, USA) to visualize specific antigens, and counterstained with 10 μg/mL of propidium iodide (PI) (Sigma Aldrich Co.) for 30 min at room temperature to label the nuclei. While Alexa Fluor 647 emits a red fluorescent signal (665 nm), the color of this signal was altered to blue in our images to distinguish it from that of PI (617 nm). A negative control was obtained using normal IgG instead of primary antibody. As a positive control expressing ESR1, activated (implantation-induced) blastocysts were collected at 23 h after E 2 injection for delayed implantation in vivo according to previously described methods (Saito et al., 2014) . The embryos were mounted on glass bottom dishes (Nippon Genetics Co. Ltd, Tokyo, Japan) and observed under an FV1000-D confocal scanning laser microscope (Olympus, Tokyo, Japan). At least 15 blastocysts from more than four animals were used for each experiment. The fluorescence intensity was measured using ImageJ software (National Institutes of Health, Bethesda, MD, USA) as described previously (Alarcon, 2010; Lord et al., 2013) .
Embryo transfer
Embryo transfer was performed as described previously (Matsumoto et al., 2002 (Matsumoto et al., , 2012 Saito et al., 2014) . After culturing for 24 h, six blastocysts were suspended in HEPES-buffered KSOM-P medium and transferred into the uteri of recipient mice on the morning of Day 4 (0900-1000 h) of pseudopregnancy. Untreated blastocysts (control) and blastocysts treated for 24 h were transferred into distinct uterine horns in each recipient. The number of implantation sites was then recorded on Day 6 using the blue dye method, as previously described (Paria et al., 1993b (Paria et al., , 2001 Saito et al., 2014) .
Statistical analyses
Cell numbers in the blastocysts were compared by one-way factorial ANOVA followed by Fisher's protected least significant difference test. Student's t test was used to evaluate differences in implantation rates, in the cell numbers of the blastocysts, and in fluorescence intensities. The data are presented as mean ± SEM; P < 0.05 was considered statistically significant. Statistical analyses were performed using StatView 4.5 (Abacus Concepts, Berkeley, CA, USA).
Results
PRL, EGF and 4-OH-E 2 promote BRCA1 level in blastocysts in vitro
Immunohistochemical analysis detected low levels of BRCA1 expression in IVF-derived blastocysts. After 24 h stimulation with PRL, EGF or 4-OH-E 2 , however, BRCA1 protein was clearly observed in the TE nuclei ( Fig. 1A-C) . Meanwhile, there was no difference in blastocyst cell numbers between the control and stimulated cultures (P > 0.05; Fig. 1D ). These results suggest that PRL, EGF and 4-OH-E 2 each promote BRCA1 protein level, but not cell proliferation in blastocysts.
BRCA1-expressing blastocysts induced with PRL, EGF or 4-OH-E 2 exhibit differential expression of EGFR, ERBB4 and TINAGL1
Given that treatment with PRL, EGF or 4-OH-E 2 resulted in enhanced BRCA1 protein level, we hypothesized that other proteins expressed in activated blastocysts might also be upregulated by these factors. BRCA1, EGFR and ERBB4 are upregulated in the TE of implantationinduced blastocysts, while TINAGL1 localizes to the blastocyst basement membrane (Raab et al., 1996; Paria et al., 1999; Hamatani et al., 2004; P = 0.033, respectively) . (E) Comparison of fluorescence intensities of immunostaining for BRCA1 and ERBB4 between control and PRL. Fluorescence intensity of BRCA1 in the PRL-treated blastocysts was significantly higher than that of the control, whereas ERBB4 was not upregulated by PRL (P values in BRCA1 and ERBB4 were P = 0.031 (a versus b) and P = 0.917 (a), respectively). (F) Comparison of fluorescence intensities of immunostaining for BRCA1 and TINAGL1 between control and PRL. Fluorescence intensity of BRCA1 in the PRL-treated blastocysts was significantly higher than that of the control, whereas TINAGL1 was not upregulated by PRL (P values in BRCA1 and ERBB4 were P < 0.001 (a versus b) and P = 0.908 (a), respectively). The data are mean ± SEM. Student's t test was used to evaluate differences in fluorescence intensities. Numbers above each bar indicate examined numbers of blastocysts. Igarashi et al., 2009; Saito et al., 2014) . Therefore, we examined the expression and localization patterns of EGFR, ERBB4 and TINAGL1 in blastocysts by immunohistochemistry. Analysis of fluorescence intensities indicated that PRL treatment resulted in increased level of EGFR (1.49 ± 0.21-fold increase, P = 0.033; Fig. 2A and D) , while neither ERBB4 (1.03 ± 0.22-fold increase, P = 0.917; Fig. 2B and E) nor TINAGL1 (0.98 ± 0.15-fold increase, P = 0.908; Fig. 2C and F) were upregulated by PRL in blastocysts exhibiting increased BRCA1 level (2.18 ± 0.29-, 2.02 ± 0.47-and 2.17 ± 0.29-fold increase, respectively; P = 0.001, P = 0.031 and P < 0.001, respectively; Fig. 2D-F) . EGF treatment resulted in increased levels of EGFR (1.37 ± 0.12-fold increase, P = 0.023; Fig. 3A and D) and ERBB4 (1.45 ± 0.18-fold increase, P = 0.039; Fig. 3B and E), whereas TINAGL1 was not upregulated by EGF (0.95 ± 0.12-fold increase, P = 0.775; Fig. 3C and F) in blastocysts exhibiting increased BRCA1 level (1.94 ± 0.29-, 2.07 ± 0.38-and 2.03 ± 0.17-fold increase, respectively; P = 0.011, P = 0.022 and P < 0.001, respectively; Fig. 3D-F) . Meanwhile, 4-OH-E 2 did not stimulate the levels of EGFR (1.13 ± 0.27-fold increase, P = 0.436; Fig. 4A and D) and ERBB4 (0.98 ± 0.09-fold increase, P = 0.939; Fig. 4B and E), while TINAGL1 was upregulated by 4-OH-E 2 (1.63 ± 0.21-fold increase, P = 0.035; Fig. 4C and F) in blastocysts exhibiting increased BRCA1 level (2.04 ± 0.27-, 1.97 ± 0.18-and 2.02 ± 0.46-fold increase, respectively; P = 0.005, P < 0.001 and P = 0.048, respectively; Fig. 4D-F) . In addition, 4-OH-E 2 promoted TINAGL1 expression in the TE as well as the localization of this protein to the basement membrane beneath the TE (Fig. 4C) . These results suggest that PRL, EGF and 4-OH-E 2 target different signaling pathways in blastocysts.
Treatment of blastocysts with the combination of PRL, EGF and 4-OH-E 2 results in enhanced expression of EGFR, ERBB4, TINAGL1 and BRCA1
Although PRL, EGF and 4-OH-E 2 each promoted BRCA1 level in blastocysts, the expression patterns of other proteins induced by these molecules were different (Figs 2-4) . Therefore, we examined the expression of EGFR, ERBB4, TINAGL1 and BRCA1 in blastocysts cultured with the combination of PRL, EGF and 4-OH-E 2 by immunofluorescence microscopy. Treatment with 20 mIU/mL PRL, 10 ng/mL EGF and 10 nM 4-OH-E 2 (PEC) resulted in increased levels of each of the factors tested, i.e. EGFR, ERBB4, TINAGL1 and BRCA1, in the TE (Fig. 5A-C) . Moreover, analysis of fluorescence intensities indicated that PEC treatment yielded a significant increase in the protein expression of EGFR (1.30 ± 0.10-fold increase, P = 0.020; Fig. 5D ), ERBB4 (1.69 ± 0.17-fold increase, P = 0.002; Fig. 5E ) and TINAGL1 (1.52 ± 0.18-fold increase, P = 0.032; Fig. 5F ) in blastocysts exhibiting increased BRCA1 protein (2.03 ± 0.15-, 2.07 ± 0.33-and 2.11 ± 0.27-fold increase, respectively; P < 0.001, P = 0.008 and P = 0.001, respectively; Fig. 5D-F) . Furthermore, PEC promoted TINAGL1 localization to the blastocyst basement membrane beneath the TE (Fig. 5C) . Conversely, combined treatment with PRL, EGF and 4-OH-E 2 did not stimulate cell proliferation (P = 0.304; Fig. 5G ). These results suggest that treatment with the combination of PRL, EGF and 4-OH-E 2 , and the induction of their respective signaling pathways, results in the upregulation of BRCA1 as well as differential spatiotemporal expression of other proteins in blastocysts, but not in cell proliferation within blastocysts.
ESR1 expression is not affected by treatment with PRL, EGF and 4-OH-E 2
ESR1 is expressed in activated blastocysts, but is degraded at the completion of blastocyst implantation (Saito et al., 2014) . Our results show that treatment with PEC promoted the expression of proteins marking activated blastocysts (Fig. 5) , suggesting that ESR1 expression might also be induced. However, immunohistochemical analysis indicated that ESR1 level was not upregulated in the BRCA1-expressing blastocysts induced with PEC (Fig. 6 ).
Combined treatment with PRL, EGF and 4-OH-E 2 improves blastocyst implantation rates
Immunohistochemical analysis suggested that the blastocysts treated with PEC could have a high potential for successful implantation. To evaluate this possibility, IVF-derived blastocysts were cultured in the presence or absence of PRL, EGF or/and 4-OH-E 2 , and then transferred into the uteri of pseudopregnant recipient mice. Treatment with PRL, EGF or 4-OH-E 2 alone did not improve blastocyst implantation rates (P > 0.05; Fig. 7A-C) . Indeed, the implantation rates of blastocysts treated with 20 mIU/mL PRL (56.1 ± 4.1%), 10 ng/mL EGF (45.4 ± 8.1%) and 10 nM 4-OH-E 2 (65.2 ± 7.9%) were not significantly different from those of the respective control populations (47.0 ± 8.0%, 43.9 ± 8.2% and 51.5 ± 9.1%; P = 0.162, P = 0.449 and P = 0.136, respectively; Fig. 7A-C) . In contrast, the implantation rate of blastocysts cultured with PEC was significantly higher than that of the control (71.2 ± 9.0% versus 36.4 ± 8.0%; P = 0.009; Fig. 7D ). These results suggest that combined treatment with PRL, EGF and 4-OH-E 2 improves the potential of blastocysts during peri-implantation.
Discussion
Blastocyst implantation competency is a prerequisite for successful pregnancy; therefore, the poor quality of the IVF embryos is one of the major causes of implantation failure (Urman et al., 2005; Cha et al., 2012) . In the present study, we show that the combination of PRL, EGF and 4-OH-E 2 appears to result in the upregulation of at least two distinct mechanisms, i.e. signaling via EGF receptors and basement significantly higher than that of the control (P values of a versus b in BRCA1 and ERBB4 were P = 0.022 and P = 0.039, respectively). (F) Comparison of fluorescence intensities of immunostaining for BRCA1 and TINAGL1 between control and EGF. Fluorescence intensity of BRCA1 in the EGFtreated blastocysts was significantly higher than that of the control, whereas TINAGL1 was not upregulated by EGF (P values in BRCA1 and ERBB4 were P < 0.001 (a versus b) and P = 0.775 (a), respectively). The data are mean ± SEM. Student's t test was used to evaluate differences in fluorescence intensities. Numbers above each bar indicate examined numbers of blastocysts. Comparison of fluorescence intensities of immunostaining for BRCA1 and EGFR between control and 4-OH-E 2 . Fluorescence intensity of BRCA1 in the 4-OH-E 2 -treated blastocysts was significantly higher than that of the control, whereas EGFR was not upregulated by 4-OH-E 2 (P values in BRCA1 and ERBB4 were P = 0.005 (a versus b) and P = 0.436 (a), respectively). (E) Comparison of fluorescence intensities of immunostaining for BRCA1 and membrane formation, thereby enhancing the implantation competency of these blastocysts in mice. Meanwhile, BRCA1 expression appears to be unnecessary for attachment reaction of blastocysts.
The expression of EGFR and ERBB4 is upregulated in implantationinduced blastocysts in vivo (Paria et al., 1993a (Paria et al., , 1999 Raab et al., 1996) . These receptors bind heparin-binding EGF-like growth factor (HB-EGF) protein, which appears on the surface of the uterine luminal epithelium as the attachment reaction commences, suggesting that peri-implantation blastocysts are targeted by HB-EGF during implantation (Das et al., 1994; Paria et al., 1999) . These events position HB-EGF and its receptors to mediate blastocyst adhesion and trophoblast differentiation (Fritz et al., 2014) . The EGF receptors undergo phosphorylation and stimulate subcellular tyrosine kinase activity after ligand binding (Ushiro and Cohen, 1980; Schlessinger, 1986; Carpenter, 1987) . In blastocysts, HB-EGF-induced EGF receptor phosphorylation advances trophoblast adhesive differentiation, i.e. induced trafficking of integrin subunits, including integrin α5, into the plasma membrane of trophoblast cells promotes their adhesion to fibronectin in the maternal extracellular matrix (Das et al., 1994; Paria et al., 1999; Wang et al., 2000; Fritz et al., 2014) . Our present results show that EGF stimulated the level of both EGFR and ERBB4 in IVFderived blastocysts, and that PRL promoted EGFR level; however, neither PRL nor EGF improve the blastocyst implantation. Therefore, levels of EGFR and ERBB4 in the blastocysts may not be enough to interact with uterine HB-EGF to complete the downstream pathway via EGF receptors.
In contrast to individual treatment, combined treatment with PRL, EGF and 4-OH-E 2 resulted in enhanced expression of EGFR, ERBB4 and TINAGL1 in the TE of murine IVF-derived blastocysts, as well as improved blastocyst implantation rates. In the cultured cells, PRL antagonizes EGF on EGFR tyrosine phosphorylation (Quijano and Sheffield, 1998) . However, in the blastocysts, EGFR phosphorylation is induced by HB-EGF in the uterine luminal epithelium (Das et al., 1994; Paria et al., 1999; Wang et al., 2000; Fritz et al., 2014) . Therefore, if PRL antagonizes EGF on tyrosine phosphorylation in blastocysts treated with combination of PRL, EGF and 4-OH-E 2 , attachment potential in blastocysts may be unaffected at embryo transfer. It is possible that sufficient EGFR and ERBB4 expression in blastocysts is likely to be important before transfer into uteri, followed by phosphorylation induced by HB-EGF in the uterine luminal epithelium to complete the trophoblast adhesive differentiation.
In cells derived from human and chinese hamster, EGF downregulates expression of EGFR (Huang et al., 2006; Li et al., 2008; Roepstorff et al., 2009; Vene et al., 2015) and most likely through ubiquitination of EGFR followed by lysosome degradation (Roepstorff et al., 2009 ). In the mouse embryo, EGF upregulates EGFR expression (Kim et al., 1999; Dadi et al., 2007) . Meanwhile, EGF stimulates DNA, RNA, and protein synthesis, cell proliferation, cavitation, blastocyst expansion and trophoblast outgrowth (Wood and Kaye, 1989; Paria and Dey, 1990; Dardik and Schultz, 1991; Adamson, 1993; Haimovici and Anderson, 1993; Machida et al., 1995) . Similarly, PRL enhances the in vitro development of mouse embryos that express PRL receptor (Yohkaichiya et al., 1988; Kiapekou et al., 2005) . However, our present results show that EGF and PRL did not stimulate cell proliferation in the blastocysts. Therefore, the roles played by EGF and PRL in implantation potential in blastocysts are most likely different from their roles in developing embryos during the preimplantation period.
A previous study revealed that 4-OH-E 2 upregulates the binding of EGF to dormant blastocysts in vitro, and those blastocysts are capable of implanting after embryo transfer (Paria et al., 1998) . Although, the binding of EGF to blastocysts was used as a marker for blastocyst activation (Paria et al., 1998) , neither EGFR nor ERBB4 were upregulated by 4-OH-E 2 in the present study. In contrast, 4-OH-E 2 promoted the expression and localization of TINAGL1 to the basement membrane beneath the TE. The basement membrane consists predominantly of laminins and collagens secreted by the TE and the parietal endoderm of the preimplantation embryos (Li et al., 2003) , which then enter the implantation stage (Bedzhov and Zernicka-Goetz, 2014) . Therefore, 4-OH-E 2 is likely to play a role in the basement membrane formation during the peri-implantation period for IVF-derived blastocysts.
TINAGL1 is a matricellular protein that interacts with structural matrix proteins and cell surface receptors, and is a component of the basement membrane . Laminins constitute the major basement membrane component (Timpl, 1996) . Laminin 1 deficient embryos lacked basement membranes and did not survive beyond embryonic Day (E)5.5 during the post-implantation period (Smyth et al., 1999; Miner et al., 2004; Alpy et al., 2005) . The attachment reaction is initiated at 2400 h on Day 4 of pregnancy . We previously demonstrated that TINAGL1 was localized to the basement membrane at 2300 h, just prior to attachment reaction, while laminin 1 was expressed in both the TE and inner cell mass (Igarashi et al., 2009 ). Subsequently, laminin 1 colocalized with TINAGL1 in the TE of implanted blastocysts (E4.5). Therefore, TINAGL1 localization to the blastocoel surface, rather than laminin in the TE, could be an early indication of basement membrane formation in the blastocysts.
Post-translational regulation, including degradation of specific proteins by the proteasome, is associated with trophoblast differentiation (Armant, 2005; Jain et al., 2016) . Our previous study demonstrated that activated blastocysts are implantation-induced, whereas those exhibiting selective proteasomal degradation of ESR1 are implantationcompetent (Saito et al., 2014) . In contrast, ESR1 expression was not upregulated in blastocysts treated with PRL, EGF and 4-OH-E 2 , which exhibited an improved implantation rate after embryo transfer. These ERBB4 between control and 4-OH-E 2 . Fluorescence intensity of BRCA1 in the 4-OH-E 2 -treated blastocysts was significantly higher than that of the control, whereas ERBB4 was not upregulated by 4-OH-E 2 (P values in BRCA1 and ERBB4 were P < 0.001 (a versus b) and P = 0.939 (a), respectively). (F) Comparison of fluorescence intensities of immunostaining for BRCA1 and TINAGL1 between control and 4-OH-E 2 . Fluorescence intensities of BRCA1 and TINAGL1 in the 4-OH-E 2 -treated blastocysts were significantly higher than that of the control (P values of a versus b in BRCA1 and TINAGL1 were P = 0.048 and P = 0.035, respectively). The data are mean ± SEM. Student's t test was used to evaluate differences in fluorescence intensities. Numbers above each bar indicate examined numbers of blastocysts. Figure 5 Combined treatment with PRL, EGF and 4-OH-E 2 results in upregulation of EGFR, ERBB4 and TINAGL1 in BRCA1-expressing mouse blastocysts. Blastocysts formed at 90-96 h after IVF were treated with the combination of 20 mIU/mL PRL, 10 ng/mL EGF and 10 nM 4-OH-E 2 (PEC) for 24 h and analyzed for (A) BRCA1 and EGFR expression, (B) BRCA1 and ERBB4 expression and (C) BRCA1 and TINAGL1 expression. Single and Composite represent, respectively, one layer and composite confocal images generated from multiple z-planes acquired at 3.0-μm intervals across the blastocyst. Arrowheads indicate the localization of the basement membrane. Scale bar, 50 μm. (D) Comparison of fluorescence intensities of immunostaining for BRCA1 and EGFR between control and PEC. Fluorescence intensities of BRCA1 and EGFR in the PEC-treated blastocysts were significantly higher than that of the control (P values of a versus b in BRCA1 and EGFR were P < 0.001 and P = 0.020, respectively). (E) Comparison of fluorescence intensities of immunostaining for BRCA1 and ERBB4 between control and PEC. Fluorescence intensities of BRCA1 and ERBB4 in the findings suggest that the improved implantation rate of the blastocysts stimulated with PRL, EGF and 4-OH-E 2 in vitro may be underlined by mechanisms that are distinct from those occuring in vivo, where uterine-derived metabolites, including 4-OH-E 2 , activate blastocysts to the implantation-induced status. However, our present results confirm that ESR1 downregulation could potentially be used to assess the implantation competency of IVF-derived blastocysts.
While treatment with PRL, EGF and 4-OH-E 2 individually resulted in stimulation of BRCA1 expression, these factors did not improve the implantation potential of the blastocysts derived from IVF. The proliferative activity during embryonic growth and differentiation of the diploid trophoblast tissue of Brca1-deficient embryos is severely impaired at E6.5, resulting in lethality before E7.5 (Hakem et al., 1996) . Our present results show that cell number in blastocysts was not affected by treatment with PRL, EGF and/or 4-OH-E 2 . These results suggest that BRCA1 is dispensable for cell proliferation and attachment potential in preimplantation blastocysts. BRCA1 may play a role in the promotion of cellular proliferation in the blastocysts during the post-implantation period, which is later than Day 7 of pregnancy (E6.5).
In conclusion, treatment of IVF-derived mouse blastocysts with PRL, EGF and 4-OH-E 2 resulted in upregulation of EGFR and ERBB4, and also promoted TINAGL1 and its localization to the basement membrane, without affecting ESR1 levels. Furthermore, this treatment enhanced the implantation ability of the cultured blastocysts. Therefore, analysis of spatiotemporal protein expression patterns, including signaling pathways via EGF receptors and basement membrane formation, may be a useful approach for evaluating IVF-derived blastocysts. In humans, ERBB4 is expressed by the trophoblast cells of peri-implantation blastocysts, suggesting that HB-EGF present in the luminal epithelium can stimulate the blastocyst through paracrine or juxtacrine signaling (Chobotova et al., 2002; Fritz et al., 2014) . Furthermore, laminin protein is highly expressed in the human TE (Niakan and Eggan, 2013) , consistent with laminin localization in the mouse TE (Niakan et al., 2010) . Therefore, combined treatment with PRL, EGF and 4-OH-E 2 might also be of relevance for embryo transfer of human blastocysts derived from IVF for ART.
PEC-treated blastocysts were significantly higher than that of the control (P values of a versus b in BRCA1 and ERBB4 were P = 0.008 and P = 0.002, respectively). (F) Comparison of fluorescence intensities of immunostaining for BRCA1 and TINAGL1 between control and PEC. Fluorescence intensities of BRCA1 and TINAGL1 in the PEC-treated blastocysts were significantly higher than that of the control (P values of a versus b in BRCA1 and TINAGL1 were P = 0.001 and P = 0.032, respectively). (G) Cell numbers in untreated blastocysts and blastocysts treated with PEC. Combined treatment of PRL, EGF and 4-OH-E 2 did not stimulate cell proliferation (a, P = 0.304). The data are mean ± SEM. Student's t test was used to evaluate differences in fluorescence intensities, and in the cell numbers of the blastocysts. Numbers above each bar indicate examined numbers of blastocysts. Figure 6 Treatment of mouse blastocysts with the combination of PRL, EGF and 4-OH-E 2 has no effect on ESR1 expression. Blastocysts formed at 90-96 h after IVF were treated with the combination of 20 mIU/mL PRL, 10 ng/mL EGF and 10 nM 4-OH-E 2 (PEC) for 24 h, and BRCA1 and ESR1 expression was then analyzed. Single (A) and Composite (B) represent, respectively, one layer and composite confocal images generated from multiple z-planes acquired at 3.0-μm intervals across the blastocyst. (C) Positive control expressing ESR1 (activated (implantation-induced) blastocysts). (D) Negative control. Scale bar, 50 μm.
Figure 7
In vitro treatment with the combination of PRL, EGF and 4-OH-E 2 results in improved mouse blastocyst implantation rates. Implantation rates after embryo transfer of IVF-derived blastocysts treated with (A) 20 mIU/mL PRL, (B) 10 ng/mL EGF, or (C) 10 nM 4-OH-E 2 , and with (D) a combination of these factors (PEC). Six untreated blastocysts (−, control) and six treated blastocysts (+) were transferred into distinct uterine horns in each recipient. The data are mean ± SEM of the data obtained from 11 independent experiments. Treatment with PRL, EGF or 4-OH-E 2 alone did not improve blastocyst implantation rates (a, P > 0.05; A-C), whereas the implantation rates of the PEC-treated blastocysts were significantly higher than those of the control population (a versus b, P = 0.009; D). Student's t test was used to evaluate differences in implantation rates.
